SG48087G - Orally administrable antidiabetic compositions - Google Patents

Orally administrable antidiabetic compositions

Info

Publication number
SG48087G
SG48087G SG48087A SG48087A SG48087G SG 48087 G SG48087 G SG 48087G SG 48087 A SG48087 A SG 48087A SG 48087 A SG48087 A SG 48087A SG 48087 G SG48087 G SG 48087G
Authority
SG
Singapore
Prior art keywords
compositions
active substance
activity
solvent
added
Prior art date
Application number
SG48087A
Other languages
English (en)
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of SG48087G publication Critical patent/SG48087G/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG48087A 1983-06-08 1987-05-30 Orally administrable antidiabetic compositions SG48087G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833320583 DE3320583A1 (de) 1983-06-08 1983-06-08 Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
SG48087G true SG48087G (en) 1987-08-28

Family

ID=6200886

Family Applications (1)

Application Number Title Priority Date Filing Date
SG48087A SG48087G (en) 1983-06-08 1987-05-30 Orally administrable antidiabetic compositions

Country Status (24)

Country Link
US (2) US4708868A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0128482B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6075435A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR910004572B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE49886T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU562803B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1228300A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD223360A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3320583A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK162018C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8601697A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI85218C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2142235B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR82363B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK72287A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU192407B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE57792B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL72033A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY100764A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO168629C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ208416A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT78711B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG48087G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA844295B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5312924A (en) 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
FR2577437A1 (fr) * 1985-02-21 1986-08-22 Corbiere Jerome Nouveau procede de solubilisation des composes chimiques et les preparations aqueuses ainsi obtenues
DE3927882A1 (de) * 1989-08-23 1991-02-28 Bauer Kurt Heinz Hochwirksame, schnell resorbierbare zubereitungsformen von glibenclamid, verfahren zu ihrer herstellung und ihre verwendung
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
EP0567541B1 (en) * 1991-01-16 1998-10-07 Fmc Corporation Carrier for active agents, and solid dosage forms prepared therewith
ATE184279T1 (de) * 1991-06-21 1999-09-15 Boehringer Ingelheim Pharma Verwendung von (s)(+)-2-äthoxy-4-(n-(1-(2- piperidino-phenyl)-3-methyl-1- butyl>aminocarbonylmethyl>-benzoesäure zur herstellung eines langzeitantidiabetikums
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5246710A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5246711A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US6004958A (en) * 1997-02-05 1999-12-21 Fox Chase Cancer Center Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
US7071298B2 (en) * 1997-02-05 2006-07-04 Fox Chase Cancer Center Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
KR100858856B1 (ko) 1999-02-08 2008-09-17 인타르시아 세라퓨틱스 인코포레이티드 안정한 비수성 단일상 점성 비히클 및 그 비히클을이용하는 제형물
CN1352558B (zh) * 1999-05-21 2012-06-13 橘生药品工业株式会社 即释型口服用药物组合物
JP2005503360A (ja) 2001-06-29 2005-02-03 エウランド ファルマチェウティカルズ リミテッド 架橋ポリマーに添加される水不溶性の薬剤の熱力学的活性化の方法
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
EP1429744A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
DK1429734T3 (da) * 2001-09-21 2008-05-13 Egalet As Faste dispersioner af carvedilol til kontrolleret afgivelse
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
WO2004045622A1 (en) * 2002-11-15 2004-06-03 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004025159D1 (de) * 2003-03-26 2010-03-04 Egalet As Matrixzubereitungen für die kontrollierte Darreichung von Arzneistoffen
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1895989A2 (en) * 2005-06-03 2008-03-12 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101516347A (zh) * 2006-09-29 2009-08-26 诺沃-诺迪斯克有限公司 包含二甲双胍和瑞格列奈的药物制剂
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス,インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2228066A1 (en) * 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
EP2462246B1 (en) 2009-09-28 2017-09-06 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
SI3412302T1 (sl) 2014-10-24 2021-09-30 Bristol-Myers Squibb Company Modificirani FGF-21 polipeptidi in njihova uporaba
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN115671203B (zh) * 2022-11-24 2023-10-27 广州中医药大学科技产业园有限公司 一种用于降糖降脂的中药复方提取物及其提取方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668215A (en) * 1967-11-25 1972-06-06 Bayer Ag Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups
NL138933B (nl) * 1969-03-26 1973-05-15 Erba Carlo Spa Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking.
US3708486A (en) * 1969-04-17 1973-01-02 Boehringer Sohn Ingelheim 2-(p-(n'-cycloalkyl-carbamido-n-sulfonyl)-phenethyl)-1,2,3,4-tetrahydro-1,3-dioxo-4,4-dimethyl-isoquinolines and alkali metal salts thereof
NL7314765A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-10-31 1974-05-02
DE2657382A1 (de) * 1976-12-17 1978-06-29 Thera Ges Fuer Patente Orales antidiabetikmittel
JPS6026093B2 (ja) * 1978-03-14 1985-06-21 住友製薬株式会社 ゲフアルナート含有固型製剤の製造方法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
EP0045238B1 (en) * 1980-07-29 1986-10-01 Sanofi S.A. Acid stabilized compositions of thieno-pyridine derived compounds and process for preventing degradation of such compounds
US4430339A (en) * 1980-08-29 1984-02-07 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung Substituted oxiranecarboxylic acids, their preparation and their use as medicaments
DE3100535A1 (de) * 1981-01-10 1982-08-12 Dr. Karl Thomae Gmbh, 7950 Biberach "neue carbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3225188A1 (de) * 1982-07-06 1984-01-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue phenylessigsaeurederivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
GB2118040A (en) * 1982-02-15 1983-10-26 Hoechst Uk Ltd Oral anti-diabetic preparation
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
DK162018B (da) 1991-09-09
DE3320583A1 (de) 1984-12-13
DK280884A (da) 1984-12-09
PT78711B (de) 1986-10-21
EP0128482A2 (de) 1984-12-19
KR850000241A (ko) 1985-02-26
KR910004572B1 (ko) 1991-07-06
PT78711A (de) 1984-07-01
US4873080A (en) 1989-10-10
IL72033A0 (en) 1984-10-31
ES533207A0 (es) 1985-11-16
JPS6075435A (ja) 1985-04-27
DD223360A5 (de) 1985-06-12
FI85218B (fi) 1991-12-13
DK280884D0 (da) 1984-06-07
EP0128482A3 (en) 1986-06-25
NZ208416A (en) 1987-06-30
FI85218C (fi) 1992-03-25
MY100764A (en) 1991-02-15
HUT34349A (en) 1985-03-28
HK72287A (en) 1987-10-16
HU192407B (en) 1987-06-29
AU2924184A (en) 1984-12-13
IE841422L (en) 1984-12-08
GB2142235A (en) 1985-01-16
FI842295A0 (fi) 1984-06-07
DE3481170D1 (de) 1990-03-08
NO168629C (no) 1992-03-18
GR82363B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-12-13
IL72033A (en) 1987-08-31
EP0128482B1 (de) 1990-01-31
ATE49886T1 (de) 1990-02-15
US4708868A (en) 1987-11-24
AU562803B2 (en) 1987-06-18
NO168629B (no) 1991-12-09
FI842295L (fi) 1984-12-09
GB8414528D0 (en) 1984-07-11
ES8601697A1 (es) 1985-11-16
DK162018C (da) 1992-02-10
CA1228300A (en) 1987-10-20
NO842291L (no) 1984-12-10
IE57792B1 (en) 1993-04-07
JPH0548206B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-07-20
GB2142235B (en) 1987-04-08
ZA844295B (en) 1986-02-26

Similar Documents

Publication Publication Date Title
SG48087G (en) Orally administrable antidiabetic compositions
GB2142236B (en) Oral antidiabetic compositions